The treatment goal algorithm for psoriasis, first originated in 2007, has ever since been adopted into treatment guidelines. It remained unclear how many patients have experienced the use of treatment goals in routine care and how these are perceived. The aim of the pilot study was to get first insight in the use and impact of therapeutic goals in a large cohort of patients with psoriasis in routine care. This study is a multicenter, non-interventional, cross-sectional health care study in n = 213 dermatology centers across Germany. A standardized physician and patient questionnaire was used, including demographics, disease and treatment characteristics. To evaluate patient treatment perception and satisfaction, a questionnaire (PsoSat) addressing 8 specific items was designed. Consistency and validity of the questionnaire were controlled by factor analyses and reliability tests. In total n = 1,883 patients were included for analysis (54.2 % male). Mean age was 52 years, mean disease duration 19 years. In total 45.5 % (n = 856) stated an improvement of psoriatic symptoms in the last 4 weeks. In patients including treatment goals, the course of psoriasis in the last 4 weeks was rated significantly better and predicted significantly higher patient satisfaction. Patients reporting periodic outcomes measurement of psoriasis treatment, also had significantly better course of disease, higher satisfaction and a lower psoriasis severity. A majority of patients experienced the use of treatment goals in practice. The association of using treatment goals with clinical outcomes and treatment satisfaction was markedly positive. These findings indicate that the use of treatment goals and outcome measurements in fact improve psoriasis management.
This is a preview of subscription content, access via your institution.
Buy single article
Instant access to the full article PDF.
Price excludes VAT (USA)
Tax calculation will be finalised during checkout.
Augustin M, Glaeske G, Schäfer I, Rustenbach SJ, Hoer A, Radtke MA (2012) Processes of psoriasis health care in Germany—long-term analysis of data from the statutory health insurances. J Dtsch Dermatol Ges 10:648–655
Augustin M, Reich K, Reich C, Purwins S, Jeff Rustenbach S, Schäfer I, Radtke MA (2008) Quality of psoriasis care in Germany—results of the national study PsoHealth 2007. J Dtsch Dermatol Ges 6:640–645
Finlay AY, Khan GK (1994) Dermatology Life Quality Index (DLQI)—a simple practical measure for routine clinical use. Clin Exp Dermatol 19(3):210–216
Mrowietz U (2012) Implementing treatment goals for successful long-term management of psoriasis. J Eur Acad Dermatol Venereol 26(Suppl 2):12–20
Mrowietz U, Kragballe K, Nast A, Reich K (2011) Strategies for improving the quality of care in psoriasis with the use of treatment goals—a report on an implementation meeting. J Eur Acad Dermatol Venereol 25(Suppl 3):1–13
Mrowietz U, Kragballe K, Reich K, Griffiths CE, Gu Y, Wang Y, Rozzo SJ (2013) An assessment of adalimumab efficacy in three Phase III clinical trials using the European Consensus Programme criteria for psoriasis treatment goals. Br J Dermatol 168(2):374–380
Mrowietz U, Kragballe K, Reich K, Spuls P, Griffiths CE, Nast A et al (2011) Definition of treatment goals for moderate to severe psoriasis: a European consensus. Arch Dermatol Res 303(1):1–10
Nast A, Boehncke WH, Mrowietz U, Ockenfels HM, Philipp S, Reich K et al (2012) S3—Guidelines on the treatment of psoriasis vulgaris (English version). Update. J Dtsch Dermatol Ges 10(Suppl 2):S1–S95
Puig L (2013) Induction phase, primary endpoint, time to decide on primary failure, and therapeutic goals in biologic treatment of psoriasis. J Eur Acad Dermatol Venereol 27(2):e257–e260
Puig L, Morales-Múnera CE (2013) Implementing therapeutic goals in maintenance treatment of psoriasis with biologics: adalimumab can be more cost-effective than infliximab or ustekinumab in real life. Eur J Dermatol 23(3):407–408
Radtke MA, Reich K, Blome C, Kopp I, Rustenbach SJ, Schäfer I, Augustin M (2009) Evaluation of quality of care and guideline-compliant treatment in psoriasis. Development of a new system of quality indicators. Dermatology 219:54–58
Reich K, Mrowietz U (2007) Treatment goals in psoriasis. J Dtsch Dermatol Ges 5(7):566–574
The study has been supported by a research grant from Biogen Idec GmbH, Ismaning, Germany.
Augustin M, Reich K and Radtke MA have conducted clinical studies, investigations in health services research, consultations or have been invited speakers for Abbvie, Biogen Idec, Janssen, MSD Sharp & Dohme, Pfizer, Merck Serono, Novartis, Medac, Lilly-Pharma and Celegene. Spehr C has no conflicts of interest to declare.
Rights and permissions
About this article
Cite this article
Radtke, M.A., Reich, K., Spehr, C. et al. Treatment goals in psoriasis routine care. Arch Dermatol Res 307, 445–449 (2015). https://doi.org/10.1007/s00403-014-1534-y
- Treatment goals
- Quality of care